Intravitreal bevacizumab (avastin) combined with vitrectomy for recurrences of proliferative vitreoretinopathy in von Hippel–Lindau disease

Tano, Ryotaro; Kakurai, Keigo; Sakurai, Toshiya; Fujiwara, Ritsuko; Mano, Tomoo; Maeno, Takatoshi

doi:10.1111/j.1755-3768.2011.02108.x

Cited by 7 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though exudation was suppressed, hemangioblastoma volumes remained stable. 153 Hrisomalos et al reported a similar response in one VHL patient, after a regimen of 12 bevacizumab injections over 60 months. 154 Tsai et al published contradictory results: photodynamic therapy in combination with intravitreal bevacizumab and corticosteroids reduced the volume of multiple retinal hemangioblastomas in one VHL patient, but exudation was not affected.…”

Section: Monoclonal Antibodiesmentioning

confidence: 81%

<p>Von Hippel-Lindau Disease: Current Challenges and Future Prospects</p>

Gläsker¹,

Vergauwen²,

Koch³

et al. 2020

OTT

View full text Add to dashboard Cite

Understanding of molecular mechanisms of tumor growth has an increasing impact on the development of diagnostics and targeted therapy of human neoplasia. In this review, we summarize the current knowledge on molecular mechanisms and their clinical implications in von Hippel-Lindau (VHL) disease. This autosomal dominant tumor syndrome usually manifests in young adulthood and predisposes affected patients to the development of benign and malignant tumors of different organ systems mainly including the nervous system and internal organs. A consequent screening and timely preventive treatment of lesions are crucial for patients affected by VHL disease. Surgical indications and treatment have been evaluated and optimized over many years. In the last decade, pharmacological therapies have been evolving, but are largely still at an experimental stage. Effective pharmacological therapy as well as detection of biomarkers is based on the understanding of the molecular basis of disease. The molecular basis of von Hippel-Lindau disease is the loss of function of the VHL protein and subsequent accumulation of hypoxia-inducible factor with downstream effects on cellular metabolism and differentiation. Organs affected by VHL disease may develop frank tumors. More characteristically, however, they reveal multiple separate microscopic foci of neoplastic cell proliferation. The exact mechanisms of tumorigenesis in VHL disease are, however, still not entirely understood and knowledge on biomarkers and targeted therapy is scarce.

show abstract

Section: Monoclonal Antibodiesmentioning

confidence: 81%

<p>Von Hippel-Lindau Disease: Current Challenges and Future Prospects</p>

Gläsker¹,

Vergauwen²,

Koch³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…22 Extravascular leakage of various growth factors might also contribute to ERM recurrence. 23 Moreover, CD, pigment release during endodrainage, inflammation and other factors are reportedly associated with the incidence of ERM. [22][23][24] Most of these factors are clearly associated with inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…23 Moreover, CD, pigment release during endodrainage, inflammation and other factors are reportedly associated with the incidence of ERM. [22][23][24] Most of these factors are clearly associated with inflammation. Thus, antiinflammatory strategies (eg, steroid use) may be effective in the prevention of ERM.…”

Section: Discussionmentioning

confidence: 99%

Risk factors for epiretinal membrane in eyes with primary rhegmatogenous retinal detachment that received silicone oil tamponade

Pan

Gao

et al. 2022

Br J Ophthalmol

View full text Add to dashboard Cite

Background/aimsThis study investigated the risk factors for epiretinal membrane (ERM) in eyes with primary rhegmatogenous retinal detachment (RRD) that received silicone oil (SO) tamponade.MethodsThis retrospective analysis included 1140 patients (1140 eyes) with RRD who underwent primary vitrectomy and SO tamponade. The prevalence of ERM was estimated and possible risk factors (eg, type 2 diabetes, proliferative vitreoretinopathy (PVR), SO tamponade time (SOTT), photocoagulation, vitreous haemorrhage, choroidal detachment, cryotherapy and retinal tear size) were analysed via multiple logistic regression.ResultsThe prevalence of ERM was 12.3% (140/1140), and the accuracy of preoperative ERM diagnosis was 40.5%. Multivariate logistic regression analysis showed that risk factors for ERM in eyes with SO tamponade included preoperative PVR (OR=4.336, 95% CI 2.533 to 7.424, p<0.001), type 2 diabetes (OR=3.996, 95% CI 2.013 to 7.932, p<0.001), photocoagulation energy (OR=1.785, 95% CI 1.306 to 2.439, p<0.001) and SOTT (OR=1.523, 95% CI 1.261 to 1.840, p<0.001). No statistically significant associations were observed between the incidence of ERM and other risk factors. Preoperative PVR showed the strongest association with risk of ERM. The risk of ERM was positively associated with SOTT, photocoagulation energy and preoperative PVR grade.ConclusionIn eyes with RRD that received SO tamponade, the prevalence of ERM was 12.3%, while the accuracy of preoperative ERM diagnosis was low. Preoperative PVR, type 2 diabetes, photocoagulation energy and SOTT were the main risk factors for ERM.

show abstract

“…Studies have shown that the use of anti-VEGF drug bevacizumab in patients with metastatic renal cancer can improve the survival rate of patients to some extent ( 44 ). However, bevacizumab may have a moderate impact on retinal HBs ( 45 , 46 ). The use of the receptor tyrosine kinase inhibitor sunitinib can reduce the volume of PHEOs as well as renal and pancreatic tumors ( 47 ).…”

Section: Discussionmentioning

confidence: 99%

VHL syndrome without clear family history: A rare case report and literature review of Chinese patients

Xin²,

Song³

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

ObjectiveTo analyze the clinical manifestations and imaging features of a hospitalized patient with intermittent headache who was finally diagnosed with von Hippel–Lindau (VHL) syndrome and to perform whole-exon gene detection to improve the understanding of the diagnosis and treatment strategies of the disease.MethodsA case of suspected VHL syndrome in Shanxi Provincial People's Hospital was analyzed. Proband DNA was also extracted for whole exome sequencing and screened for causative mutation sites, which were validated by Sanger sequencing. The literature about VHL gene mutations in Chinese patients in the past 10 years were also reviewed.ResultsThere is a heterozygous mutation site c.499C > G on the VHL gene on the short arm of chromosome 3 of the patient, which is a missense mutation. The mutation results in the substitution of arginine with glycine at amino acid 167 of the encoded protein, which may be primarily responsible for the disease in the patient with VHL syndrome. However, the mutation did not occur in other family members.ConclusionEarly recognition and treatment of VHL syndrome can be available with genetic testing technology. Strengthening the understanding of this complex genetic disease and improving the diagnostic rate of VHL syndrome are helpful for the precise treatment of patients with this disease, which may help prolong the survival time of patients to a certain extent and improve their quality of life.

show abstract

Intravitreal bevacizumab (avastin) combined with vitrectomy for recurrences of proliferative vitreoretinopathy in von Hippel–Lindau disease

Cited by 7 publications

References 5 publications

<p>Von Hippel-Lindau Disease: Current Challenges and Future Prospects</p>

<p>Von Hippel-Lindau Disease: Current Challenges and Future Prospects</p>

Risk factors for epiretinal membrane in eyes with primary rhegmatogenous retinal detachment that received silicone oil tamponade

VHL syndrome without clear family history: A rare case report and literature review of Chinese patients

Contact Info

Product

Resources

About